Home / Market News / $PETS
benzinga Corporate Catalyst Impact 55/100 ● negative

Morgan Stanley Maintains Underweight on PetMed Express, Lowers Price Target to $1.4

Sep 25, 2026, 4:51 PM UTC · Primary ticker $PETS

Morgan Stanley analyst Erin Wright reiterated an Underweight rating on PetMed Express and significantly lowered its price target from $2.15 to $1.4. This analyst action suggests a more pessimistic outlook on the company's future performance, likely impacting investor sentiment negatively.

Morgan Stanley's analyst Erin Wright maintained an 'Underweight' rating on PetMed Express (PETS) and substantially reduced the price target from $2.15 to $1.4. This action indicates a continued bearish outlook on the company's fundamentals and future prospects. The lowered price target suggests that the analyst sees significant downside risk or limited upside potential for PETS shares in the short to medium term. This could lead to negative investor sentiment and potential selling pressure on the stock, as institutional investors often consider analyst ratings and price targets in their investment decisions. For traders, this implies a potential short-term negative catalyst, with long-term implications depending on whether the company can address the underlying issues leading to this pessimistic view.

$PETS negative Price target lowered, rating maintained Underweight
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.